Abstract 2045P
Background
The success of cancer therapy relies on patient adherence, which refers to the extent to which a person's behaviour - taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider ( WHO 2003 ). Several PROMs were developed to measure patient adherence to (cancer) therapy. In light of this, our study aims to offer a comprehensive overview of PROMs in the cancer field, with a specific focus on the adherence dimensions captured.
Methods
A systematic review of systematic reviews was performed to identify studies of cancer patients that apply PROMs to measure adherence without restriction to the type of therapy. Databases of Pubmed and Embase were searched up to March 2022 and studies were selected based on predefined eligibility criteria. A qualitative synthesis was used determining measurement of adherence and dimensions of PROMs according to the WHO definition for adherence.
Results
After screening 4483 results a total of 56 literature reviews were included capturing 1064 studies that focused on cancer patients. Out of the 56 literature reviews included in our final analysis, the majority (45) focused on medication adherence, while 18 studies assessed adherence to dietary recommendations, and 13 studies examined adherence to lifestyle changes. Three studies investigated other dimensions of adherence. Data collection was primarily carried out via questionnaires and most studies applied self-developed, non-validated PROMs. PROMs mainly measured one dimension of adherence, even though the content of items were overlapping between medication, diet and lifestyle.
Conclusions
This systematic literature review provides a comprehensive overview of PROMs used to assess adherence in oncology. Our analysis highlights the predominance of studies measuring medication adherence and underscores the need for greater attention to other dimensions of adherence. Our findings can inform the choice of PROMs to monitor patients’ adherence in clinical practice and enhance health outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06